Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Queensland Health
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,705,520

« Back to Dashboard

Summary for Patent: 5,705,520

Title: Medicaments
Abstract:The present invention, relates to 3-[2-(dimethylamino)ethyl]-N-methyl-1H-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof, and to pharmaceutical compositions containing same. The compound is useful in the treatment of conditions associated with cephalic pain, in particular migraine. The pharmaceutical compositions are particularly useful as intranasal formulations.
Inventor(s): Craig; Joanne (Ware, GB3), Crookes; Derek Leslie (Ware, GB3), Skittrall; Stephen John (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:08/651,961
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,705,520

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9026998Dec 12, 1990

International Patent Family for Patent: 5,705,520

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic9301140► Subscribe
Ireland62894► Subscribe
China1050831► Subscribe
Cyprus2005► Subscribe
Czech Republic281931► Subscribe
Germany69108200► Subscribe
Denmark0490689► Subscribe
Egypt20219► Subscribe
European Patent Office0490689► Subscribe
Spain2069836► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: